ADR Biomedical Holdings (TSE:3750) Cyclically Adjusted Revenue per Share: 円202.92 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3750 ADR Biomedical Holdings Inc TSE:3750
23 GF Score
Price 円822.00
GF Value 円38.97
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Cyclically Adjusted Revenue per Share?

ADR Biomedical Holdings TSE:3750 -1.67% 23 Cyclically Adjusted Revenue per Share is 円202.92 as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 23/100 and a GF Value™ of 円38.97 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ADR Biomedical Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was 円1.937. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円202.92 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ADR Biomedical Holdings was -14.50% per year. The lowest was -35.10% per year. And the median was -16.70% per year.

As of today (2026-09-04), ADR Biomedical Holdings's current stock price is 円822.00. ADR Biomedical Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円202.92. ADR Biomedical Holdings's Cyclically Adjusted PS Ratio of today is 4.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ADR Biomedical Holdings was 4.16. The lowest was 0.22. And the median was 3.15.


ADR Biomedical Holdings  (TSE:3750) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ADR Biomedical Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=822.00/202.92
=4.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ADR Biomedical Holdings was 4.16. The lowest was 0.22. And the median was 3.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ADR Biomedical Holdings Cyclically Adjusted Revenue per Share Related Terms


ADR Biomedical Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Cyclically Adjusted Revenue per Share Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 358.28 325.11 279.27 0.00 202.92

ADR Biomedical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.37 220.76 216.27 202.92 0.00

TSE:3750 vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, ADR Biomedical Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADR Biomedical Holdings Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ADR Biomedical Holdings's Cyclically Adjusted PS Ratio falls into.


TSE:3750
23GF Score
ADR Biomedical Holdings Inc TSE:3750
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ADR Biomedical Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.937/112.7000*112.7000
=1.937

Current CPI (Mar. 2026) = 112.7000.

ADR Biomedical Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 92.440 97.900 106.415
201606 21.767 98.100 25.007
201609 83.187 98.000 95.665
201612 94.797 98.400 108.573
201703 184.286 98.100 211.713
201706 14.454 98.500 16.538
201709 3.506 98.800 3.999
201712 1.483 99.400 1.681
201803 57.737 99.200 65.594
201806 252.065 99.200 286.368
201809 8.704 99.900 9.819
201812 15.287 99.700 17.280
201903 10.643 99.700 12.031
201906 10.345 99.800 11.682
201909 10.350 100.100 11.653
201912 72.138 100.500 80.895
202003 83.018 100.300 93.281
202006 21.695 99.900 24.475
202009 44.128 99.900 49.782
202012 41.998 99.300 47.665
202103 56.930 99.900 64.224
202106 52.745 99.500 59.742
202109 23.468 100.100 26.422
202112 41.845 100.100 47.112
202203 33.135 101.100 36.937
202206 60.873 101.800 67.391
202209 70.468 103.100 77.030
202212 53.656 104.100 58.089
202303 55.199 104.400 59.587
202306 52.921 105.200 56.694
202309 43.689 106.200 46.363
202312 61.498 106.800 64.895
202403 16.667 107.200 17.522
202406 4.426 108.200 4.610
202409 5.815 108.900 6.018
202503 0.000 111.100 0.000
202506 0.688 111.700 0.694
202509 1.360 112.000 1.369
202512 1.727 113.000 1.722
202603 1.937 112.700 1.937

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円202.92 mean?
ADR Biomedical Holdings (TSE:3750) has a Cyclically Adjusted Revenue per Share of 円202.92 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Cyclically Adjusted Revenue per Share too high?
ADR Biomedical Holdings' current Cyclically Adjusted Revenue per Share is 円202.92. Overall, ADR Biomedical Holdings has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
ADR Biomedical Holdings' Cyclically Adjusted Revenue per Share of 円202.92 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Cyclically Adjusted Revenue per Share is 円202.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円38.97, compared to a current price of 円822.00 — trading 2009.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円202.92. ADR Biomedical Holdings' overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Cyclically Adjusted Revenue per Share is 円202.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円822.00 is trading 2009.3% above its estimated GF Value™ of 円38.97. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Cyclically Adjusted Revenue per Share: 円202.92
  • GF Value™: 円38.97 vs. price of 円822.00 (2009.3% above fair value)
  • GF Score™: 23/100 with 7 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
23GF Score

Get the complete analysis for TSE:3750

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円822.00
Price
円38.97
GF Value